

## Bulletin from the Extraordinary General Meeting in LIDDS AB (PUBL) on 27 February 2024

The Extraordinary General Meeting in LIDDS AB (PUBL) (“LIDDS” or the “Company”) was held on 27 February 2024 and in particular the following decisions were resolved.

- The Extraordinary General Meeting resolved to approve the Board of Directors' resolution to acquire all shares in Noviga Research AB. The agreed purchase price for the shares in Noviga shall be paid by the Sellers subscribing for and being allocated 68,231,663 shares in LIDDS AB.
- The Extraordinary General Meeting resolved to adopt new articles of association where the provision on the limits of the share capital in § 4 is amended to not less than 3,604,000 and not more than 14,416,000, the provision on the number of shares in § 5 is amended to not less than 68,000,000 and not more than 272,000,000 shares, the provision regarding the Company's registered office in § 2 is changed to Gothenburg, and the provision on the description of the business in § 3 is changed to “The Company shall, directly or indirectly through subsidiaries, conduct research, development, production and out-licensing of pharmaceuticals and activities compatible therewith” (Sw. Bolaget ska direkt eller indirekt genom dotterbolag bedriva forskning, utveckling, framtagning och utlicensiering av läkemedel och därmed förenlig verksamhet).
- The Extraordinary General Meeting resolved that the Company's share capital shall be increased by not more than SEK 3,616,278.139 through a directed issue of not more than 68,231,663 new shares against payment in kind consisting of all shares in Noviga Research AB. The issue is subject to the so-called Leo rules (Chapter 16 of the Swedish Companies Act) as the Company's Chairman Daniel Lifveredson and Board Members Torbjörn Browall and Lars-Inge Sjöqvist, in their capacity as a shareholders in Noviga Research AB are included in the group of persons entitled to subscribe for shares.
- The Extraordinary General Meeting resolved to authorise the Board of Directors to, on one or more occasions during the period until the next Annual General Meeting, with or without preferential rights for the shareholders, decide on an issue of shares. It shall be possible for the issue to take place with or without regulation on payment in cash, non-cash contributions, set-off or other conditions. The number of shares that it shall be possible to issue can amount to a maximum of a number equivalent to thirty-five per cent of the total number of shares in the Company at the time of the Extraordinary General Meeting.

Notice and complete proposals are available on the Company's website: <https://liddspharma.com/en/corporate-governance/>

**For additional information, please contact**

---

Jenni Björnulfson, CEO and CFO  
Phone: +46 (0)70 855 38 05  
E-mail: [jenni.bjornulfson@liddspharma.com](mailto:jenni.bjornulfson@liddspharma.com)

LIDDS' Certified Adviser is Redeye AB

**LIDDS in brief:**

---

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. LIDDS offers the NanoZolid technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. The company is listed on Nasdaq First North Growth market.

**Attachments**

---

**Bulletin from the Extraordinary General Meeting in LIDDS AB (PUBL) on 27 February 2024**